- Home
- PERI vs BCYC Comparison
PERI vs BCYC Comparison
Compare PERI & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PERI
- BCYC
- Stock Information
- Founded
- PERI 1999
- BCYC 2009
- Country
- PERI Israel
- BCYC United Kingdom
- Employees
- PERI N/A
- BCYC N/A
- Industry
- PERI EDP Services
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- PERI Technology
- BCYC Health Care
- Exchange
- PERI Nasdaq
- BCYC Nasdaq
- Market Cap
- PERI 412.5M
- BCYC 492.1M
- IPO Year
- PERI 2006
- BCYC 2019
- Fundamental
- Price
- PERI $9.64
- BCYC $8.37
- Analyst Decision
- PERI Buy
- BCYC Buy
- Analyst Count
- PERI 4
- BCYC 11
- Target Price
- PERI $11.83
- BCYC $22.91
- AVG Volume (30 Days)
- PERI 242.5K
- BCYC 300.4K
- Earning Date
- PERI 11-05-2025
- BCYC 10-30-2025
- Dividend Yield
- PERI N/A
- BCYC N/A
- EPS Growth
- PERI N/A
- BCYC N/A
- EPS
- PERI N/A
- BCYC N/A
- Revenue
- PERI $424,098,000.00
- BCYC $19,281,000.00
- Revenue This Year
- PERI N/A
- BCYC N/A
- Revenue Next Year
- PERI $11.40
- BCYC N/A
- P/E Ratio
- PERI N/A
- BCYC N/A
- Revenue Growth
- PERI N/A
- BCYC N/A
- 52 Week Low
- PERI $7.00
- BCYC $6.10
- 52 Week High
- PERI $11.79
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- PERI 52.95
- BCYC 67.78
- Support Level
- PERI $9.36
- BCYC $7.40
- Resistance Level
- PERI $9.83
- BCYC $8.69
- Average True Range (ATR)
- PERI 0.27
- BCYC 0.38
- MACD
- PERI 0.03
- BCYC 0.17
- Stochastic Oscillator
- PERI 61.33
- BCYC 82.98
About PERI Perion Network Ltd.
Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.